The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| NAII | -34.91% | -62.59% | -17.84% | -18% |
| S&P | +12.65% | +91.73% | +13.89% | +1,531% |
Natural Alternatives International, Inc. engages in the manufacturing, distribution, and marketing of vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. It operates through Private-Label Contract Manufacturing and Royalty, Licensing, and Raw Material Sales segments. The Private-Label Contract Manufacturing segment provides manufacturing services to companies that market and distribute nutritional supplements and other health care products. The Royalty, Licensing, and Raw Material Sales segment is associated with the sale and license of beta-alanine. The company was founded by Mark A. LeDoux in 1980 and is headquartered in Carlsbad, CA.
No news articles found for Natural Alternatives International.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $33.73M | 14.4% |
| Gross Profit | $3.40M | 139.4% |
| Gross Margin | 10.07% | 5.3% |
| Market Cap | $20.27M | -45.7% |
| Market Cap / Employee | $0.09M | 0.0% |
| Employees | 234 | -24.5% |
| Net Income | -$7.22M | -285.1% |
| EBITDA | $0.58M | 143.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $12.33M | 2.9% |
| Accounts Receivable | $14.64M | -13.3% |
| Inventory | 24.9 | 2.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $54.60M | -1.4% |
| Short Term Debt | $4.43M | -9.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -8.03% | -3.3% |
| Return On Invested Capital | 3.04% | -2.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $1.89M | 150.4% |
| Operating Free Cash Flow | $3.35M | 223.1% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.43 | 0.33 | 0.27 | 0.26 | -40.41% |
| Price to Sales | 0.30 | 0.21 | 0.16 | 0.16 | -50.01% |
| Price to Tangible Book Value | 0.43 | 0.33 | 0.27 | 0.26 | -40.41% |
| Price to Free Cash Flow TTM | 8.42 | 5.55 | 8.74 | - | |
| Enterprise Value to EBITDA | -193.33 | -47.56 | -62.57 | 116.27 | -282.59% |
| Free Cash Flow Yield | 11.9% | 18.0% | 11.4% | - | |
| Return on Equity | -10.1% | -9.3% | -10.2% | -18.0% | 113.44% |
| Total Debt | $63.43M | $61.67M | $58.43M | $59.03M | -2.09% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
